Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIETTA regimen in diffuse large B-cell lymphoma with central nervous system involvement
2014-003031-19Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, rituximab, cytarabine, ifosfamide, carboplatin and 4 more in diffuse large B-cell lymphoma (DLBCL) and secondary central nervous system lymphoma (SCNSL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: 1-year progression-free survival. Started Oct 2014; status: completed.
02
Drugs
methotrexaterituximabcytarabineifosfamidecarboplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on 2014-003031-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003031-19.